What would be the study design for gliclazide 80mg tablet for Europe, WHO & HKG [Regulatives / Guidelines]

posted by prasad.v – India, 2021-07-29 10:33 (333 d 17:41 ago) – Posting: # 22486
Views: 1,996

Dear All,

Little bit confusion raised as the Gliclazide is a NTI molecule, what would be the study design for gliclazide 80mg tablet BE study for Europe, WHO & HKG submission.
  1. Can we do the two-way crossover or full replicate fast and fed by widening AUC?
  2. Can we do the two-way crossover or full replicate fast and fed by widening AUC and Cmax?

Regards,
V. Prasad

Complete thread:

UA Flag
Activity
 Admin contact
22,178 posts in 4,646 threads, 1,571 registered users;
online 4 (0 registered, 4 guests [including 3 identified bots]).
Forum time: Tuesday 04:14 CEST (Europe/Vienna)

It is futile to do with more things
that which can be done with fewer.    William of Ockham

The Bioequivalence and Bioavailability Forum is hosted by
BEBAC Ing. Helmut Schütz
HTML5